| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456354 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(14 years from now) | |
| US11110054 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(14 years from now) | |
Prevduo is owned by Slayback Pharma Llc.
Prevduo contains Glycopyrrolate; Neostigmine Methylsulfate.
Prevduo has a total of 2 drug patents out of which 0 drug patents have expired.
Prevduo was authorised for market use on 23 February, 2023.
Prevduo is available in solution;intravenous dosage forms.
The generics of Prevduo are possible to be released after 25 October, 2038.
Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
PREVDUO family patents
